Incidental Histopathologic Findings of Uterine Leimyosarcoma in a 58-year-old Woman: A Rare Case Report
Abstract
Introduction: Leiomyosarcoma accounts for (~40–50%) of all uterine sarcomas, but only 1-2% of all uterine malignancies. The incidence of leiomyosarcoma increases with age, reaching its peak in the seventh decade of life. Here, we proposed the importance of macroscopic and microscopic criteria of leiomyosarcoma to ensure clinical diagnosis.
Case Presentation: A 58-year-old woman came with vaginal bleeding for 3 weeks before admission to the hospital. The ultrasonography (USG) examination showed enlargement of the uterus and was clinically diagnosed as a leiomyoma. However, on histopathological examination, a proliferation of anaplastic cells was revealed, forming fasciculi that intersect each other and infiltrate into the connective tissue stroma. Mitosis 15/50 HPF and abnormal mitosis with abrupt coagulative necrosis are easily found. The histopathologic examination concluded that the patient had uterine leiomyosarcoma (pT1a), FIGO stage 1B.
Conclusion: Histopathological examination and a clinicoradiological approach are key to identifying leiomyosarcoma. In most cases, although it is confined to the uterus, it has a poor prognosis. Otherwise, this case has a more favorable outcome due to the pathological and clinical stage, with 5-year survival rates of 40 – 70%
Keywords
DOI: 10.33371/ijoc.v19i3.1335
Article Metrics
References
Longacre TA, Herran PC, Lim D. Female Genital Tumor. In: Oliva E, Lazar JA, editors. Smooth muscle tumor, leiomyosarcoma. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020.p.242
Paudel P, Dhungana B, Shrestha E, Verma D. Leiomyosarcoma of the Uterus: A Rare Diagnosis. Cureus. 2021;13(8)
Byar KL, Fredericks T. Uterine Leiomyosarcoma. Journal of the advanced practitioner in oncology. 2022;13(1):70–76
Cao S, Liu Y, Bai X, Wang L. A Case Report of Uterine Leiomyosarcoma. OncoTargets and therapy. 2019;12:8583-86
Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562-72
Bosoteanu M, Deacu M, Voda RI, et al. Five-year retrospective study of uterine STUMP and leiomyosarcoma. Clinics and Practice. 2022;12(6): 897-907
Dunphy L, Sheridan G. Uterine leiomyosarcoma: a rare clinical entity. BMJ case reports. 2021;14(8)
George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. Journal of Clinical Oncology. 2018;36(2):144
Zheng, Rongshou Z, Siwei Z, Hongmei. Incidence of soft tissue sarcoma in China. Journal of Clinical Oncology. 2018;36
Nucci RM, Oliva E. Diagnostic pathology gynecology. 2nd edition. Salt lake city: Elsevier; 2018.p 402-406
Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecologic Oncology. 2018;151(3):562-72
Byar KL, Fredericks T. Uterine Leiomyosarcoma. Journal of the advanced practitioner in oncology. 2022;13(1):70–76
Wang L, Li S, Zhang Z, et al. Prevalence and occult rates of uterine leiomyosarcoma. Medicine. 2020;99(33):1-4
Juhasz BI, Gabriel L, Bohle RM, et al. Uterine leiomyosarcoma. Oncology research and treatment. 2018;41(11):680-86.
Sun S, Bonaffini PA, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagnostic and interventional imaging. 2019;100(10), 619-34
Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. International Journal of Gynecology & Obstetrics. 2018;143: 51-58.
Bužinskienė D, Mikėnas S, Drąsutienė G, Mongirdas M. Uterine sarcoma: a clinical case and a literature review. Acta Medica Lituanica. 2018;25(4):206
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


